A Non-Randomized, Open Label, Safety and Efficacy Study Evaluating a Single Dose of Kamuvudine-8 (K8) for the Treatment of Patients with Diabetic Macular Edema

Grants and Contracts Details

StatusFinished
Effective start/end date1/21/23 → 10/30/24

Funding

  • Inflammasome Therapeutics Incorporated: $40,000.00